NAMS
The table below shows NewAmsterdam Pharma Company N.V.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $457.61M | $538.41M | $563.86M | $748.42M | - | - |
| Short-term investments | $178.50M | $164.54M | $175.30M | $60.06M | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $658.04M |
| $732.33M |
| $769.85M |
| $817.30M |
| $437.87M |
| $445.35M |
| Property, plant & equipment | $379.00K | $323.00K | $312.00K | $238.00K | $231.00K | $234.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $732.64M | $786.43M | $815.11M | $818.41M | $439.19M | $446.69M |
| Accounts payable | $8.09M | $3.63M | $5.89M | $6.09M | $7.04M | $5.28M |
| Total current liabilities | $67.42M | $58.27M | $36.51M | $40.91M | $41.26M | $45.31M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $67.42M | $58.36M | $36.62M | $41.05M | $60.33M | $59.25M |
| Retained earnings | -$810.83M | -$687.47M | -$615.46M | -$598.10M | -$466.39M | -$449.75M |
| Total equity | $665.22M | $728.07M | $778.50M | $777.36M | $378.86M | $387.44M |